Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs
Insights
Citrate anticoagulation for continuous renal replacement therapy (CRRT) in critically ill patients significantly reduces circuit loss, filter failure, and bleeding compared to heparin. Citrate is a preferred method, especially when contraindications for heparin exist.
Area of Science:
- Nephrology
- Critical Care Medicine
- Pharmacology
Background:
- Continuous renal replacement therapy (CRRT) is vital for critically ill patients with organ dysfunction.
- Effective anticoagulation is crucial for maintaining CRRT circuit patency and function.
- Heparin and citrate are common anticoagulation methods, each with distinct risk-benefit profiles.
Purpose of the Study:
- To conduct a meta-analysis comparing the efficacy and safety of citrate versus heparin anticoagulation in CRRT.
- To evaluate the impact on circuit survival, filter failure, bleeding complications, and other adverse events.
Main Methods:
- A systematic literature search of Medline, Embase, and Cochrane databases was performed.
- Included randomized controlled trials (RCTs) comparing citrate and heparin for CRRT anticoagulation.
- Meta-analysis of data from 11 RCTs involving 992 patients and 1998 circuits.
Main Results:
- Citrate significantly reduced circuit loss compared to both regional and systemic heparin.
- Citrate also decreased the incidence of filter failure and bleeding risk versus systemic heparin.
- Increased risks of heparin-induced thrombocytopenia (HIT) with heparin and hypocalcemia with citrate were noted. No survival differences were found.
Conclusions:
- Regional citrate anticoagulation demonstrates superior performance in CRRT compared to heparin.
- Lower risks of circuit loss, filter failure, bleeding, and HIT support citrate as a preferred option.
- Citrate should be considered for CRRT in critically ill patients, barring specific contraindications.
Purpose:
The purpose of this study was to evaluate the effect and safety of citrate versus heparin anticoagulation for continuous renal replacement therapy (CRRT) in critically ill patients by performing a meta-analysis of updated evidence.
Methods:
Medline, Embase, and Cochrane databases were searched for eligible studies, and manual searches were also performed to identify additional trials. Randomized controlled trials (RCTs) assessing the effect of citrate versus heparin anticoagulation for CRRT were considered eligible for inclusion.
Results:
Eleven RCTs with 992 patients and 1998 circuits met the inclusion criteria. Heparin was regionally delivered in two trials and systemically delivered in nine trials. Citrate for CRRT significantly reduced the risk of circuit loss compared to regional (HR 0.52, 95 % CI 0.35–0.77, P = 0.001) and systemic (HR 0.76, 95 % CI 0.59–0.98, P = 0.04) heparin. Citrate also reduced the incidence of filter failure (RR 0.70, 95 % CI 0.50–0.98, P = 0.04). The citrate group had a significantly lower bleeding risk than the systemic heparin group (RR 0.36, 95 % CI 0.21–0.60, P < 0.001) and a similar bleeding risk to the regional heparin group (RR 0.34, 95 % CI 0.01–8.24, P = 0.51). The incidences of heparin-induced thrombocytopenia (HIT) and hypocalcemia were increased in the heparin and citrate groups, respectively. No significant survival difference was observed between the groups.
Conclusions:
Given the lower risk of circuit loss, filter failure, bleeding, and HIT, regional citrate should be considered a better anticoagulation method than heparin for CRRT in critically ill patients without any contraindication.
Related Concept Videos
01:30Continuous Renal Replacement Therapy
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:20Acute Kidney Injury V: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:28Chronic Kidney Disease III: Interprofessional Care